JY
QNCX icon

Jeff Yass’s Quince Therapeutics QNCX Stock Holding History

Jeff Yass’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-863
Closed -$19.8K – 14307
2026
Q1 		$17.5K Sell
863
-862
-50% -$173K ﹤0.01% 12876
2025
Q4 		$1.16M Buy
+1,725
New +$868K ﹤0.01% 6860
2024
Q4 		– Sell
-163
Closed -$49K – 13018
2024
Q3 		$25.3K Sell
163
-330
-67% -$47.3K ﹤0.01% 11576
2024
Q2 		$74K Buy
493
+9
+2% +$1.63K ﹤0.01% 11216
2024
Q1 		$103K Sell
484
-16
-3% -$3.98K ﹤0.01% 11199
2023
Q4 		$105K Sell
500
-20
-4% -$4K ﹤0.01% 11291
2023
Q3 		$116K Sell
520
-44
-8% -$11.5K ﹤0.01% 10789
2023
Q2 		$170K Sell
564
-64
-10% -$19.9K ﹤0.01% 10448
2023
Q1 		$196K Buy
628
+108
+21% +$21.1K ﹤0.01% 10619
2022
Q4 		$66.3K Sell
520
-378
-42% -$63.2K ﹤0.01% 11239
2022
Q3 		$239K Buy
898
+144
+19% +$54.9K ﹤0.01% 10394
2022
Q2 		$335K Buy
754
+100
+15% +$70.7K ﹤0.01% 9273
2022
Q1 		$809K Sell
654
-1,771
-73% -$2.41M ﹤0.01% 7693
2021
Q4 		$6.12M Buy
2,425
+2,130
+722% +$13M ﹤0.01% 3419
2021
Q3 		$5.41M Buy
295
+54
+22% +$859K ﹤0.01% 3812
2021
Q2 		$2.55M Sell
241
-160
-40% -$1.34M ﹤0.01% 5379
2021
Q1 		$2.89M Buy
+401
New +$2.89M ﹤0.01% 5051

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's QNCX Position: Q2 2026 in Review

Jeff Yass sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 863 shares — an estimated $19.8K sold.

Jeff Yass first reported a position in QNCX in Q1 2021 and held it in 17 quarters. The position peaked at $6.12M in Q4 2021. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Jeff Yass reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 863 Quince Therapeutics shares in Q2 2026, an estimated $19.8K.
  • Jeff Yass first reported a position in Quince Therapeutics in Q1 2021 and held it in 17 quarters.
  • Jeff Yass's Quince Therapeutics position peaked at $6.12M in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.